Each year, an estimated 300,000 adults in the United States die of causes related to obesity [2] According to the guidelines of the National Institute of Health (NIH) regarding the treatment of obesity, weight loss drugs approved by the FDA [US Food and Drug Administration] may only be used as part of a comprehensive weight loss program, including dietary therapy and physical activity, for patients with a BMI [body mass index] of 30 with no concomitant obesity-related risk factors or diseases, and for patients with a BMI of 27 with concomitant obesity-related risk factors or diseases[3].The risk factors and diseases considered important enough to warrant pharmacotherapy at a BMI of 27--29.9 are hypertension, dyslipidemia, coronary heart disease (CHD), type 2 diabetes, and sleep apnea [3]
Some metallodrugs have been synthesized and tested for their combined, SOD and catalase scavenging activities
Further studies are required to better understand how GGT1, other GGT family members and uncharacterized proteins with GGT activity contribute to extracellular GSH catabolism
There is not a single test to diagnose chronic fatigue syndrome
Somatostatin noncompetitively inhibits GH and other hormone secretion
GHRPs are short peptides, typically consisting of about six amino acids, that were initially developed as analogs of opiate drugs
